UPC stock forecast, quote, news & analysis
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being... Show more
Why Universe Pharmaceuticals (UPC) Stock Is Down -54% in the Last 30 Days
Key Takeaways
- Universe Pharmaceuticals (UPC) has fallen roughly 54% over the last 30 days, sliding from about $4.58 to approximately $2.11, including a single-session decline of more than 33% on Oct. 26.
- Dilution concerns tied to an effective mixed-shelf registration and a conditional 10-for-1 reverse split approved at the company's 2026 annual meeting sit at the center of the selloff.
- Ongoing Nasdaq listing-compliance risk and minimum bid-price pressure continue to weigh on investor sentiment.
- Shareholder investigations announced by two law firms and an independent ratings downgrade added to the negative news flow.
- Weak fundamentals, including negative trailing earnings, compound the stock's technical and fundamental deterioration.
- Over the last quarter, the stock is down roughly 39%, reflecting a broader multi-month downtrend punctuated by sharp volatility.
- For additional detail, explore UPC's Price Targets, Earnings, and Forecast pages.
- For automated trading ideas, explore Trending AI Robots.
Universe Pharmaceuticals (UPC) Company Overview and Market Position
Universe Pharmaceuticals INC (NASDAQ: UPC) is a China-based pharmaceutical producer and distributor headquartered in Ji'an, Jiangxi province. The company specializes in manufacturing, marketing, selling, and distributing traditional Chinese medicine derivative (TCMD) products aimed primarily at elderly patients, including chronic-condition treatments and cold-and-flu medications such as Guben Yanling Pill, Shenrong Weisheng Pill, Isatis Root Granule, and Qiangli Pipa Syrup. It also distributes third-party biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its products are sold across 30 provinces in China, with customers that include pharmaceutical companies, hospitals, clinics, and drugstore chains. Listed on the Nasdaq Capital Market since March 2021, UPC is a micro-cap company that investors follow for its exposure to China's aging population and the TCMD market, as well as for the governance and listing-compliance risks that have repeatedly affected its shares.
Universe Pharmaceuticals (UPC) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, UPC has fallen roughly 54%, declining from about $4.58 to approximately $2.11. The move was concentrated in the final stretch of October: the shares closed at $2.88 on Oct. 26, a single-session decline of more than 33%, and continued to trade lower intraday in the following session.
The last quarter tells a similar but broader story. From roughly $3.45 in late July, the stock is down about 39%, despite an early-August surge that briefly pushed the shares above $6.00 on unusually heavy volume. That spike proved short-lived, and the stock has trended lower since, underscoring a sustained downtrend rather than a one-off event.
What Drove UPC Stock Price in the Last 30 Days
Several overlapping factors drove the sharp decline. At its 2026 annual general meeting, shareholders approved a conditional 10-for-1 reverse split designed to trigger automatically if the stock closes below roughly $1.00 for three consecutive trading days, a measure intended to preserve Nasdaq listing compliance but one that highlighted persistent minimum bid-price risk. Separately, a mixed-shelf registration statement was declared effective in early October, raising the prospect of future share issuance and diluting investor confidence. In addition, two law firms announced shareholder investigations concerning potential fiduciary-duty breaches, and an independent ratings provider downgraded the stock. The combination of dilution overhang, listing uncertainty, and negative news flow culminated in the sharp Oct. 26 decline.
What Drove UPC Stock Performance Over the Last Quarter
The quarterly downtrend reflects deeper, structural concerns rather than a single catalyst. UPC has a history of Nasdaq deficiency notices and repeated reverse splits to address minimum bid-price requirements, which has kept listing risk in the foreground for months. Weak financial results, including negative trailing earnings, have limited fundamental support, while the company's small float and thin liquidity make the shares prone to outsized moves. The early-August surge was an exception within an otherwise downward trajectory, and selling pressure resumed in the following months as dilution and governance concerns resurfaced.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a platform that offers hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, helping traders filter a large universe of automated approaches. The bots vary widely in strategy, holding timeframe, and performance metrics, so investors can review different risk profiles and trading styles rather than a single one-size-fits-all system. For those monitoring volatile, event-driven names like UPC, the page provides a way to observe how quantitative models are positioned and to explore algorithmic ideas that complement their own research. Visitors can browse the curated list to see which strategies are currently trending.
UPC Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape UPC's path forward. First, Nasdaq listing compliance remains the central watch item, particularly whether the conditional reverse split is triggered by sustained sub-$1.00 closes. Second, the effective mixed-shelf registration introduces the possibility of future share issuance, which investors will monitor for signs of additional dilution. Third, the company's financial trajectory matters: UPC has reported losses and negative earnings per share on a trailing basis, so any updates on revenue trends and profitability will be closely scrutinized. Fourth, developments in the Chinese TCMD market, including regulatory changes and demand from an aging population, remain relevant to the underlying business. Finally, the outcome of the announced shareholder investigations and broader market sentiment toward micro-cap, China-listed companies could continue to influence trading. Investors should treat these as areas to monitor rather than as predictive signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
UPC's RSI Oscillator dives oversold zone
The RSI Indicator for UPC moved into overbought territory on October 26, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +24.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where UPC advanced for three days, in 179 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
UPC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 33 cases where UPC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UPC as a result. In 79 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for UPC turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
UPC moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for UPC entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.541) is normal, around the industry mean (8.413). P/E Ratio (-0.001) is within average values for comparable stocks, (-1.728). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (0.150) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. UPC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric